CA
NZ
UK
AU
IND
US
Much of healthcare commerce happens after a product is approved: wholesalers, logistics providers andBrandowners move it from factory to pharmacy shelf or doorstep. Distribution runs onVolumeand thin margins. Cellyan Biotechnology (NASDAQ:HKPD) and Cosmos Health (NASDAQ:COSM) both make most of their money moving pharmaceutical and …
For a drug company, approval is only the halfway point. Turning a product into steady revenue depends on sales coverage, hospital formulary access, reimbursement, competition and patent protection. Heron Therapeutics (NASDAQ:HRTX) and AEON Biopharma (NYSE American:AEON) sit at opposite ends of that journey: Heron …
Q32 Bio (NASDAQ:QTTB) rose 3.0% to $9.50 in pre-market trading on heavy volume, bouncing from a deeply oversold RSI of 22.0 after a 43.6% one-month slide. The alopecia drug developer is headed to Phase 3, has new 36-week and 52-week data coming at a …
SELLAS Life Sciences (NASDAQ:SLS) rose to $12.00 in pre-market trading, outpacing biotech peers, as investors await the "imminent" Phase 3 REGAL readout for its galinpepimut-S cancerVaccinein acute myeloid leukemia. The stock has soared about 600% in a year, 29.2% of its float is sold …
Johnson & Johnson (NYSE:JNJ) rose 0.2% to $271.28 in pre-market trading after five-year CARVYKTI myeloma data reshaped long-term survival expectations. The Dow component is up 30.5% this year, near its 52-week high, and its Bollinger Band width has compressed to 5.0%, just as Apollo …
Omeros (NASDAQ:OMER) rose 3.8% to $20.90 in pre-market trading, near its 52-week high, after a finance vice president exercised options and sold stock at $20.95 under a pre-set trading plan. The biotech trades at just 14 times trailingEarningsafter the launch of Yartemlea, the first …
Intellia Therapeutics (NASDAQ:NTLA) rose 1.1% to $12.29 in pre-market trading on above-normal volume, with 33.3% of its float sold short and 14.1 days to cover. The FDA has accepted Intellia's application for lonvo-z in hereditary angioedema with priority review and a March 10, 2027 …
AVITA Medical (NASDAQ:RCEL) rose 0.5% to $11.64 after completing its PermeaDerm trial, leaving the wound-care stock just below its 52-week high and up 233.7% this year. It has outperformed the market by 181.4 percentage points over six months, helped by raised 2026 guidance and …
Enliven Therapeutics (NASDAQ:ELVN) rose 1.8% pre-market to $45.98, but its 14-day RSI of 21.1 shows the cancer-drug developer is one of the most oversold biotech stocks in the market after sliding from its August peak. The stock is still up 190.7% this year, holds …
Novavax (NASDAQ:NVAX) rose 0.94% to $10.70 as biotech stocks moved higher, leaving theVaccinemaker near its 52-week high with 30.2% of its float sold short and 9.3 days to cover. The FDA's approval of updated 2026-27 COVID vaccines, including the Novavax-Sanofi shot, and a pivot …
Please wait processing your request...